Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlobalData Plc
  6. News
  7. Summary
    DATA   GB00B87ZTG26

GLOBALDATA PLC

(DATA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

GlobalData : US COVID-19 testing shouldn't overshadow testing for other diseases such as RSV, says GlobalData

07/29/2021 | 08:49pm EDT
29 Jul 2021
US COVID-19 testing shouldn't overshadow testing for other diseases such as RSV, says GlobalData
Posted in Pharma

Following a reported rise in RSV cases in the US, leading data and analytics company GlobalData notes that the country should test COVID-19-free patients that are showing symptoms for RSV in order to address this worsening issue.

Nancy Jaser, PharmD/MBA, Pharma Analyst at GlobalData, comments:

'The recent reported surge in RSV cases in the US was hardly unexpected, as similar situations occurred in Australia and New Zealand, where the summer season occurred earlier than in the US. Healthcare professionals should now be testing SARS-CoV-2 negative patients with respiratory symptoms for RSV to prevent further complications and deaths.'

RSV vaccines and prophylaxis have been largely overshadowed by the ongoing COVID-19 pandemic. Very few cases were seen in the winter of 2020, compared to the normal annual case count. With the prevalence of cases today, companies are now able to resume trial enrolments in a race to bring improved therapies and the first ever vaccines to market.

Jaser continues: 'It is clear that vaccines are a much-needed weapon to tackle RSV, however, new monoclonal antibody nirsevimab has demonstrated major advantages in clinical trials involving infants over the current standard of care, Synagis (palivizumab).'

Nirsevimab, developed by AstraZeneca and Sanofi, has an extended half-life of up to 117 days, compared to the 20-day half-life of Synagis. A single dose can provide protection for at least five months, which covers an entire RSV season. Further, Synagis has a high price tag of up to $9,000 per year, providing an opportunity for price competition. Synagis is limited to use in high-risk pre-mature infants, while nirsevimab is intended to be used in all infants. Nirsevimab is currently in late stage pivotal trials and with FDA breakthrough designation and positive Phase 3 results, is on track to become the first new intervention approved for RSV in 23 years.*'

Jaser continues: 'While the awareness of RSV in the general population remains low, pharmaceutical companies are still working rapidly to provide the FDA with pivotal trial data to submit their vaccines and prophylactic treatments for approval. This new generation of vaccine candidates use an improved 'pre-fusion' RSV F-protein antigen. Currently, GlaxoSmithKline is on track to bring the first older adult RSV vaccine to market, while Pfizer is closest to a maternal vaccine approval. Until new interventions enter the market, it remains important to use Synagis in high-risk infants to prevent disease and associated healthcare costs.

*Qing Zhu et al, A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants

Disclaimer

GlobalData plc published this content on 29 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 July 2021 00:48:03 UTC.


ę Publicnow 2021
All news about GLOBALDATA PLC
05:42aGLOBALDATA : Applied Materials, ASML and Lam Research list over 19,000 jobs in 2021 amid s..
PU
05:42aGLOBALDATA : Nestle's new initiative highlights how upcycling can tackle APAC's mounting f..
PU
05:42aGLOBALDATA : India needs more digital public initiatives on diabetes, obesity, and mental ..
PU
05:42aGLOBALDATA : Product personalization to drive Australia make-up market at 3% CAGR through ..
PU
09/21GLOBALDATA : Cross-sector study shows auto industry as a Covid recovery leader
PU
09/21GLOBALDATA : Applied Materials, ASML and Lam Research list over 18,000 jobs in 2021 amid s..
PU
09/21GLOBALDATA : McDonald's ‘green Happy Meal' toys need recyclable options, says Global..
PU
09/21GLOBALDATA : Observability market to consolidate into automation solutions in 2022, says G..
PU
09/21GLOBALDATA : Bulgaria's defense spending increases will continue to be driven by Russia's ..
AQ
09/21GLOBALDATA : Foxconn's EV ambition to take-off in Thailand, says GlobalData
PU
More news
Financials
Sales 2021 192 M 262 M 262 M
Net income 2021 27,9 M 38,1 M 38,1 M
Net Debt 2021 50,8 M 69,4 M 69,4 M
P/E ratio 2021 66,4x
Yield 2021 1,22%
Capitalization 1 755 M 2 397 M 2 398 M
EV / Sales 2021 9,42x
EV / Sales 2022 8,69x
Nbr of Employees 3 472
Free-Float 30,8%
Chart GLOBALDATA PLC
Duration : Period :
GlobalData Plc Technical Analysis Chart | DATA | GB00B87ZTG26 | MarketScreener
Technical analysis trends GLOBALDATA PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 1 487,50 GBX
Average target price 1 592,50 GBX
Spread / Average Target 7,06%
EPS Revisions
Managers and Directors
Michael Thomas Danson Chief Executive Officer & Director
Graham Charles Lilley Chief Financial Officer, Secretary & Director
Murray Legg Independent Non-Executive Chairman
Peter Martin Harkness Independent Non-Executive Director
Catherine Birkett Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
GLOBALDATA PLC8.97%2 395
S&P GLOBAL INC.35.43%107 240
RELX PLC23.85%58 406
THOMSON REUTERS CORPORATION43.03%57 661
MSCI INC.43.48%52 821
EQUIFAX INC.36.50%31 602